Loading clinical trials...
Loading clinical trials...
The purpose of the study is to assess the impact of treatment with tolterodine ER versus placebo on Urgency Urinary Incontinence in sexually active women with OAB symptoms.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
NCT06885931 · Mixed Urinary Incontinence, Stress Urinary Incontinence (SUI), and more
NCT05989646 · Urinary Incontinence, Daytime Wetting, and more
NCT06798311 · Urinary Incontinence (UI), Lower Urinary Tract Symptoms (LUTS), and more
NCT07489794 · Multiple Sclerosis, Urinary Incontinence (UI)
NCT05362292 · Urinary Incontinence, Urge, Urinary Incontinence, and more
Pfizer Investigational Site
Chandler, Arizona
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Little Rock, Arkansas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions